Si uca1 2

Manufactured by GenePharma

Sourced in China

The Si-UCA1#2 is a laboratory equipment designed for genetic analysis. It is used for the detection and quantification of the UCA1 gene, which is associated with various diseases. The device utilizes a specific detection method to provide accurate and reliable results. Further details on the intended use or interpretation of the results are not available.

Automatically generated - may contain errors

Lab products found in correlation

Si uca1 3, by GenePharma (5 mentions) Si uca1 1, by GenePharma (5 mentions) Lipofectamine 2000 reagent, by Thermo Fisher Scientific (4 mentions) Mir 143 mimic mir 143, by RiboBio (3 mentions) Scrambled mimic control mir nc, by RiboBio (2 mentions) Scrambled sirna control si nc, by GenePharma (2 mentions) Pcdna3.1 vector, by Thermo Fisher Scientific (2 mentions) Pcdna vector, by Thermo Fisher Scientific (2 mentions) Lipofectamine 2000, by Thermo Fisher Scientific (1 mentions) Mir nc, by RiboBio (1 mentions) Si nc, by GenePharma (1 mentions) Inhibitor control anti mir nc, by RiboBio (1 mentions)

5 protocols using si uca1 2

Overexpression and Silencing of UCA1 in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

To construct UCA1 overexpression plasmid, the full length of the UCA1 cDNA sequence was amplified, cloned into pcDNA3.1 vector (Invitrogen), and sequenced and named as pcDNA3.1-UCA1 (UCA1). Three specific small interference RNAs (siRNAs) targeting UCA1 (si-UCA1#1, si-UCA1#2, and si-UCA1#3) and scrambled siRNA control (si-NC) were obtained from GenePharma (Shanghai, China). miR-143 mimic (miR-143) and scrambled mimic control (miR-NC) were purchased from RiboBio (Guangzhou, China). All these plasmids and oligonucleotides were transfected into cells by Lipofectamine 2000 reagent (Invitrogen) following the manufacturer’s instructions.

Luan Y., Li X., Luan Y., Zhao R., Li Y., Liu L., Hao Y., Oleg Vladimir B, & Jia L. (2019). Circulating lncRNA UCA1 Promotes Malignancy of Colorectal Cancer via the miR-143/MYO6 Axis. Molecular Therapy. Nucleic Acids, 19, 790-803.

+ Open protocol

+ Expand

Knockdown of lncRNA UCA1 in NPC Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

NPC in logarithmic growth stage was assigned into three groups, namely the blank group and the negative control (NC) group (cells transfected with empty plasmid) and the UCA1 siRNA group (cells transfected with UCA1 siRNA plasmid). The siRNA sequences for UCA1 were si-UCA1-1: 5ʹ-AGUAUGUUGUUUGUUGUUAGA-3ʹ (Sense) and 5ʹ-UAACAACAAACAACAUACUUU-3ʹ (Antisense), si-UCA1-2: 5ʹ-UUAAUCCAGGAGACAAAGATT-3ʹ (Sense) and 5ʹ-UCUUUGUCUCCUGGAUUAATT-3ʹ (Antisense) and si-UCA1-3: 5ʹ-GCACCUUGUUAGCUACAUAAA-3ʹ (Sense) and 5ʹ-UAUGUAGCUAACAAGGUGCCA-3ʹ (Antisense), and the sequences for NC were: 5ʹ-UUCUCCGAACGUGUCACGUTT −3ʹ (Sense) and 5ʹ-ACGUGACACGUUCGGAGAATT-3ʹ (Antisense). The empty plasmid, si-UCA1-1, si-UCA1-2 and si-UCA1-3 plasmids were purchased from Shanghai GenePharma Co., Ltd (Shanghai, China). According to the instructions of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), the cells after transfection were cultured in an incubator for 48 hours to detect the expression of UCA1.

Han R., Chen S., Wang J., Zhao Y, & Li G. (2019). LncRNA UCA1 affects epithelial-mesenchymal transition, invasion, migration and apoptosis of nasopharyngeal carcinoma cells. Cell Cycle, 18(21), 3044-3053.

+ Open protocol

+ Expand

Overexpression and Silencing of UCA1 in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

To construct UCA1 overexpression plasmid, the full length of UCA1 cDNA sequence was amplified, cloned into pcDNA vector (Invitrogen), and sequenced, named as pcDNA-UCA1 (UCA1). Three specific siRNAs targeting UCA1 (si-UCA1#1, si-UCA1#2, and si-UCA1#3) and si-NC were obtained from GenePharma (Shanghai, China). miR-143 mimic (miR-143) and miR-NC were purchased from RiboBio (Guangzhou, China). All of these plasmids and oligonucleotides were transfected into cells by Lipofectamine 2000 reagent (Invitrogen) following the manufacturer’s instructions.

Chen X., Wang Z., Tong F., Dong X., Wu G, & Zhang R. (2019). lncRNA UCA1 Promotes Gefitinib Resistance as a ceRNA to Target FOSL2 by Sponging miR-143 in Non-small Cell Lung Cancer. Molecular Therapy. Nucleic Acids, 19, 643-653.

+ Open protocol

+ Expand

UCA1 Overexpression and Silencing Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

To construct the UCA1 overexpression plasmid, the full length of UCA1 cDNA sequence was amplified, cloned into pcDNA vector (Invitrogen), and sequenced, named as pcDNA-UCA1 (UCA1). Three specific siRNAs targeting UCA1 (si-UCA1#1, si-UCA1#2, and si-UCA1#3) and scrambled siRNA control (si-NC) were obtained from GenePharma (Shanghai, China). The lentivirus vectors containing UCA1 overexpression plasmid (Lv-UCA1) or NC vector (Lv-NC) were amplified and cloned by GeneChem (Shanghai, China). The miR-143 mimic (miR-143) and scrambled mimic control (miR-NC) were purchased from RiboBio (Guangzhou, China). All these plasmids and oligonucleotides were transfected into cells by Lipofectamine 2000 reagent (Invitrogen), following the manufacturer’s instructions.

Li Z., Niu H., Qin Q., Yang S., Wang Q., Yu C., Wei Z., Jin Z., Wang X., Yang A, & Chen X. (2019). lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer. Molecular Therapy. Nucleic Acids, 17, 92-101.

+ Open protocol

+ Expand

Overexpression and Silencing of UCA1 in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Overexpressed UCA1 (pcDNA-UCA1) clones were based on the pcDNA-3.1 vector (Invitrogen). The UCA1 fragments were obtained by PCR and inserted into the XbaI/EcoRI sites. The constructs were identified and sequenced. The primers used were listed as follows: UCA1 forward primer F: 5′-CCGCTCGAGAGCGCGTGTGGCGGCCGAGCAC-3′, and UCA1 reverse primer R: 5′-CGCGGATCC AGACACGAGGCCGGCCACGCCACG-3′. Three specific siRNA targeting UCA1 (si-UCA1#1, si-UCA1#2, and si-UCA1#3) and scrambled siRNA control (si-NC) were obtained from GenePharma (Shanghai, China). The sequences were described as follows: si-UCA1#1: 5′-GGACAACAGUACACGCAUATT-3′; si-UCA1#2: 5′-GCCACCUACAUUAAAGCUATT-3′; si-UCA1#3: 5′-GACCAGACCCTACCCGGTCATTTATUATT-3′; miR-143 mimic (miR-143), scrambled mimic control (miR-NC), miR-143 inhibitor (anti-miR-143), and inhibitor control (anti-miR- NC) were purchased from RiboBio (Guangzhou, China). All these plasmids and oligonucleotides were transfected into cells by Lipofectamine 2000 reagent (Invitrogen) following the manufacturer’s instructions.

Yu Y., Gao F., He Q., Li G, & Ding G. (2019). lncRNA UCA1 Functions as a ceRNA to Promote Prostate Cancer Progression via Sponging miR143. Molecular Therapy. Nucleic Acids, 19, 751-758.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!